The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, ...

The plans, if implemented, would result in the layoff of about 365 employees. Galapagos said it will still entertain ...

The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in ...

Cost Plus Drugs is sharing pricing data with TrumpRx, the administration’s new direct-to-consumer prescription drug website ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.

A gene therapy for hearing loss, an experimental pancreatic cancer treatment and seven other medications have been chosen as the first recipients of a new voucher the Food and Drug Administration is ...

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...